Clinical trials: Cemiplimab
Head and Neck Squamous Cell Carcinoma
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
The purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT06855212
- Testing
- Cemiplimab, Cetuximab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
This study is to analyze the efficacy of PD1 inhibitor and anti-CD38 antibody in relapsed or refractory NK/T-cell lymphoid malignancy.
- Conditions
- Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma
- Trial name
- ICING (NCT04763616)
- Testing
- Isatuximab, Cemiplimab
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Won Seog Kim
Cancer, Immune-related Adverse Event
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database.
- Conditions
- Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- EXIT (NCT05934214)
- Testing
- Immune checkpoint inhibitor
- Where
- 2 sites in France
- Volunteers
- 141,630 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Provide expanded access of cemiplimab in patients with solid tumors
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06132191
- Testing
- Cemiplimab
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
- Trial name
- NCT07346196
- Testing
- Cemiplimab, Fianlimab, Carboplatin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma
Cemiplimab/Peg-Interferon-α in Advanced CSCC
The primary purpose of this research study is to test the safety and possible harms of cemiplimab/peg-interferon-alpha, when it is given to participants at different dose levels.
- Conditions
- Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
- Trial name
- NCT05729139
- Testing
- Cemiplimab-Rwlc, PEG-IFN alfa-2a
- Where
- United States
- Sponsor
- Baptist Health South Florida
Malignant Melanoma, Squamous Cell Carcinoma of Skin
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with…
- Trial name
- NCT04913220
- Testing
- THOR-707, Cemiplimab
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Sanofi
Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly…
- Trial name
- NCT04989946
- Testing
- Degarelix, pTVG-AR, Nivolumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
This phase I/II trial studies the side effects and best dose of pidnarulex when given together with cemiplimab and to see how well it works in treating patients with microsatellite stable (MSS) colorectal cancer (CRC) that does…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07147231
- Testing
- Biopsy Procedure, Biospecimen Collection, Cemiplimab
- Where
- 7 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs".
- Trial name
- NCT06246916
- Testing
- fianlimab, cemiplimab, relatlimab+nivolumab
- Where
- 113 sites in United States, Canada
- Volunteers
- 560 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated…
- Trial name
- NCT06848088
- Testing
- Fianlimab+cemiplimab
- Where
- 11 sites in United States, Ireland
- Volunteers
- 48 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma, Oropharynx Cancer
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease
- Conditions
- Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
- Trial name
- NCT05535023
- Testing
- SAR444245, Cemiplimab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Gynecological Cancer, Immunotherapy
Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.
Quantification of anti PD-1 mAbs in cancer patients is extremely important to monitor pharmacokinetics and effectiveness of immunotherapy.
- Trial name
- IMMUNO_ASSAY (NCT06797479)
- Testing
- Blood samples for the analysis of sildenafil in plasma
- Volunteers
- 12 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe…
- Conditions
- Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03916627
- Testing
- cemiplimab, Platinum Doublet, fianlimab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor…
- Trial name
- NCT05882734
- Testing
- M1774, Cemiplimab
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Squamous Cell Carcinoma of Head and Neck
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab…
- Trial name
- NCT04465487
- Testing
- REGN6569, Cemiplimab
- Where
- 10 sites in United States, Spain
- Volunteers
- 38 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of…
- Trial name
- NCT03515629
- Testing
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Colon Cancer
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
This is a research study to test whether two immunotherapy drugs-cemiplimab and fianlimab-can safely and effectively shrink colon tumors before surgery in people with stage II-III colon cancer that has not spread to other parts…
- Trial name
- NACho (NCT07224022)
- Testing
- Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Volunteers
- 24 people
- Sponsor
- John Strickler, M.D.